Pulmonary adenoma susceptibility 1 (Pas1), located on chromosome 6, is the major locus affecting inherited predisposition to lung tumor development in mice. We have fine mapped the Pas1 locus to a region of Ϸ0.5 megabases by using congenic strains of mice, constructed by placing the Pas1 region of chromosome 6 from A͞J mice onto the genetic background of C57BL͞6J mice. Systematic characterization of Pas1 candidates establishes the Las1 (lung adenoma susceptibility 1) and Kras2 (Kirsten rat sarcoma oncogene 2) genes as primary candidates for the Pas1 locus. Clearly, Kras2 affects lung tumor progression only, and Las1 is likely to affect lung tumor multiplicity. L ung cancer is the leading cause of cancer death in men and women in the United States (1). Although lung cancer is largely induced by smoking, there is strong evidence for genetic susceptibility and gene-environment interactions in its development (2-5). However, genetic heterogeneity and enormous variation in exposure levels to environmental agents make it difficult to identify lung cancer susceptibility loci in humans. Thus, inbred mouse models offer an effective means of identifying candidate lung cancer susceptibility loci (6) (7) (8) (9) (10) (11) (12) (13) (14) . Inbred strains of mice have different susceptibilities to spontaneous and carcinogen-induced lung tumor formation (6, 7). The A͞J strain is the most susceptible to lung tumorigenesis, whereas the C3H and C57BL͞6J strains are among the most resistant (6, 7). Linkage study using (A͞J ϫ C3H͞HeJ)F 2 and (A͞J ϫ C57BL͞6J)F 2 mice has demonstrated that pulmonary adenoma susceptibility 1 (Pas1) is the major lung tumor susceptibility locus in mice, which has been mapped to the distal region of chromosome 6 and accounts for Ϸ50% of the phenotypic variance (9, 10). Here we provide definitive evidence to support the candidacy of both Las1 (lung adenoma susceptibility 1) and Kras2 (Kirsten rat sarcoma oncogene 2) as the Pas1 genes on mouse chromosome 6. We are not aware of the identification of any other candidates for this quantitative trait locus (QTL) in either mouse models or humans since the initial mapping of the Pas1 QTL in 1993 (9).
L
ung cancer is the leading cause of cancer death in men and women in the United States (1) . Although lung cancer is largely induced by smoking, there is strong evidence for genetic susceptibility and gene-environment interactions in its development (2) (3) (4) (5) . However, genetic heterogeneity and enormous variation in exposure levels to environmental agents make it difficult to identify lung cancer susceptibility loci in humans. Thus, inbred mouse models offer an effective means of identifying candidate lung cancer susceptibility loci (6) (7) (8) (9) (10) (11) (12) (13) (14) . Inbred strains of mice have different susceptibilities to spontaneous and carcinogen-induced lung tumor formation (6, 7) . The A͞J strain is the most susceptible to lung tumorigenesis, whereas the C3H and C57BL͞6J strains are among the most resistant (6, 7) . Linkage study using (A͞J ϫ C3H͞HeJ)F 2 and (A͞J ϫ C57BL͞6J)F 2 mice has demonstrated that pulmonary adenoma susceptibility 1 (Pas1) is the major lung tumor susceptibility locus in mice, which has been mapped to the distal region of chromosome 6 and accounts for Ϸ50% of the phenotypic variance (9, 10) . Here we provide definitive evidence to support the candidacy of both Las1 (lung adenoma susceptibility 1) and Kras2 (Kirsten rat sarcoma oncogene 2) as the Pas1 genes on mouse chromosome 6. We are not aware of the identification of any other candidates for this quantitative trait locus (QTL) in either mouse models or humans since the initial mapping of the Pas1 QTL in 1993 (9) .
Materials and Methods
Construction of Congenic Strains. Inbred A͞J and C57BL͞6J mice were purchased from The Jackson Laboratory. The basic breeding scheme in the study was to put an Ϸ26.1-centimorgan fragment of chromosome 6, encompassed by D6MIT54 and D6MIT373 markers from the lung tumor-susceptible A͞J strain, onto the genetic background of lung tumor-resistant C57BL͞6J mice. A͞J mice were crossed initially to C57BL͞6J mice. F 1 progeny were backcrossed to C57BL͞6J mice to produce the first backcross generation (N 2 ). The N 2 generation heterozygous for the chromosome region of interest was then backcrossed again to C57BL͞6J mice to produce the N 3 generation. This process was repeated for a total of seven backcrosses. At the N 5 generation, additional microsatellite markers on chromosomes 9, 10, 17, and 19 (D9MIT75, D9MIT355, D9MIT35, D10MIT106, D10MIT2, D10MIT126, D17MIT246, D17MIT23, D17MIT50, D19MIT36, D19MIT10, and D19MIT89) were screened to obtain the optimal breeders that harbor the least amount of the non-Pas1 donor genome. At N 8 , 132 male substrains containing different chromosomal regions of interest were generated. These individual substrains were then each crossed to three C57BL͞6J females to produce the N 9 generation. After selection, an average of 5-12 N 9 congenic mice were generated from each subcongenic strain.
Genotyping Using Polymorphic Markers. For selecting mice on the basis of their genotypes throughout the Pas1 region on chromosome 6, the following markers were used: D6MIT54, D6MIT52, D6MIT59, D6MIT57, D6MCO10, D6MCO11, D6MIT15, and D6MIT373. All of the mouse microsatellite primers were purchased from Research Genetics (Huntsville, AL). The forward primer was end labeled with [ 32 P]ATP, and 30 cycles of PCR were performed at 94°C for denaturation, 55°C for annealing, and 72°C for extension. Denaturing 8% polyacrylamide gels were used for resolution of the radiolabeled PCR products, followed by autoradiography.
Lung Tumorigenesis in Congenic Mice. Five-week-old N 9 mice were given a single i.p. injection of urethane (1 mg͞g of body weight) in 0.2 ml of PBS. All animals were killed by CO 2 asphyxiation 7.5 months after urethane initiation. A portion of lung tumors plus normal tissue was removed and flash frozen in liquid nitrogen. The remaining portion was fixed in Tellyesniczky's solution and examined with the aid of a dissecting microscope to count and size the tumors. Tumor volumes were determined by measuring the threedimensional size of each tumor and by using the average of the three measurements as the diameter. The radius (diameter͞2) was determined, and the total tumor volume was calculated by the formula volume ϭ (4͞3)r 3 , where r is the radius. Two-way ANOVA was used to determine the difference in both the number and sizes of lung tumors between control and congenic groups.
Northern Blot Analysis and Semiquantitative RT-PCR. Total RNAs were prepared from mouse lung tissues by using TRIzol reagent (Life Technologies, Rockville, MD). Poly(A) ϩ RNAs were purified from the total RNAs with a MicroPoly(A)Pure kit (Ambion, Austin, TX). A 2-g aliquot of each poly(A) ϩ RNA was separated on a 1% agarose gel containing 2% formaldehyde and transferred to nylon membrane. The blots were hybridized with a randomprimed 32 P-labeled cDNA probe in ExpressHyb hybridization solution (Clontech) at 68°C, washed with 0.1ϫ SSC (1ϫ SSC ϭ 0.15 M sodium chloride͞0.015 M sodium citrate, pH 7)͞0.1% SDS at 50-65°C, and exposed for autoradiography at Ϫ80°C. For semiquantitative RT-PCR, first-strand cDNAs were synthesized by using SuperScript 2 (Life Technologies) with random primer and 1 g of poly(A) GCGGC and 3Ј-TCGAAGAAGTAGTTCTGTGGC (for Las1), and 5Ј-TGACATCCGTAAAGACCTCTATGCC and 3Ј-AAG-CAC TTGCGGTGCACGATGGAG (for ␤-actin). All reactions involved initial denaturation at 94°C for 3 min, followed by 30-35 cycles at 94°C for 30 sec, 55°C for 30 sec, and 72°C for 30 sec (for Las1), and 21 cycles at 94°C for 30 sec, 68°C for 30 sec, and 72°C for 30 sec (for ␤-actin) on a PTC-100 programmable thermal controller (MJ Research, Cambridge, MA).
Colony-Formation Assay and Athymic Mouse Tumorigenicity Assay.
To obtain the entire sequence of cDNAs, we performed rapid amplification of cDNA ends by using a Marathon cDNA amplification kit (Clontech). The entire Las1 cDNAs for both A͞J and C57BL͞6J were cloned into the pcDNA3.1(ϩ) vector (Invitrogen) with the restriction sites for HindIII and EcoRI. Various mouse lung tumor cells were used in this experiment. LM1 is a metastatic cell line derived from A͞J (15) . MC4 and MC14 cells were from chemical-induced lung tumors in B6C3 F 1 (15) . These lines and NIH 3T3 cells (mouse fibroblast cell line) were obtained from either the American Type Culture Collection or the University of Colorado (Denver). For colony-formation assay, LM1 cells were seeded at 1.5 ϫ 10 6 per 10-cm dish and transiently transfected with 4 g of the constructed and empty vectors with Lipofectamine (Invitrogen). The transfected cells were cultured in the presence of 1 mg͞ml G418 for 2 weeks. The cells that survived were fixed with 10% formalin and stained with 0.125% crystal violet. The colonies (Ն1 mm) were counted. We repeated at least three independent experiments. For athymic mouse tumorigenicity, female athymic BALB͞c nude mice aged 4-6 weeks were purchased from Charles River Breeding Laboratories. We injected 10 million cells s.c. into each flank of nude mice. Four animals were used per sample. We monitored the health of animals three times a week and measured the size of tumors weekly for 6 weeks. Tumor volume was calculated as described. We also confirmed the expression of Las1 for several tumors resected from nude mice by RT-PCR.
Immunocytochemistry. pcDNA3.1(ϩ) and N-myc-tagged Las1 expression vectors were constructed from the A͞J and C57BL͞6J alleles, individually, to identify the localization of Las1 in cells. NIH 3T3 cells transiently transfected with pcDNA3.1(ϩ) and N-myctagged Las1 were replated on multiwell chamber slides (Beckton Dickinson). The cells were then fixed with 4% paraformaldehyde in PBS and made permeable with 0.1% Triton X-100 in PBS for 3 min. Cells were covered with 3% BSA-containing blocking solution for 1 h at room temperature. The cells were then incubated with mouse anti-myc antibody (Oncogene Science; 1:50 dilution in blocking solution) for 1 h at room temperature. Anti-myc antibody was stained with goat anti-mouse secondary antibody conjugated to rhodamine (1:250 dilution) for 1 h and viewed with an Eclipse E600 microscope (Nikon).
Lung Tumorigenesis on F1 Heterozygous Kras2-Deficient Mice. Sixweek-old male 129͞Sv-K-ras ϩ/Ϫ (Kras2-knockout), A͞J female, and C57BL͞6J female mice were paired to develop breeding colonies for production of (A͞J ϫ 129͞Sv-K-ras ϩ/Ϫ )F 1 mice and (C57BL͞ 6J ϫ 129͞Sv-K-ras ϩ/Ϫ )F 1 mice. Each F 1 mouse was genotyped for the presence of the Kras2-targeted mutation and was randomized into groups according to the Kras2 genotypes and carcinogen treatments. For groups treated with urethane, animals were given a single i.p. injection of urethane (1 mg͞g of body weight) in 0.2 ml of PBS. For methylnitrosourea (MNU) treatment groups, all animals were given a single i.p. injection of MNU (50 mg͞kg of body weight) in 0.2 ml of PBS. Animals from all eight groups were killed by CO 2 asphyxiation 18-20 weeks after treatment with carcinogens. For each mouse, portions of tumors plus normal lung tissue were frozen in liquid nitrogen. The remaining tissue and tumors were fixed in Tellyesniczky's solution overnight and then treated with 70% ethanol. The tumor number and sizes were measured.
Kras2 Activity Assays. Mouse lung tumors from Kras2
ϩ/Ϫ of A͞J or C57BL͞6J mice were obtained from the lung tumor bioassays. These tumors were homogenized in lysis buffer [PBS containing 5 mM MgCl 2 , 1 mM DTT, 0.2 mM PMSF, 2 g͞ml leupeptin, 5 g͞ml aprotinin, and 1 mM benzamidine (pH 7.5)] and cleared by centrifugation. Nonidet P-40 was then added to 1% after centrifugation. Protein concentrations were determined by Bradford assay (Bio-Rad) and equalized before incubation with 40 g of GST-Raf Ras binding domain, precoupled to glutathione agarose. Half as much lysate was used in the pulldown from C57BL͞6J tumors. After 2 h of mixing, beads were washed and bound proteins were eluted with SDS sample treatment buffer. Bound Kras2 protein was detected by Western blotting with ␣-KRas2 F234 antibody (Santa Cruz Biotechnology).
Statistical Analysis. To compare the tumor multiplicity and load genotype͞genotype (Kras2 ϩ/Ϫ ͞Kras2 ϩ/ϩ ) ratios between (A͞J ϫ 129͞Sv-K-ras ϩ/Ϫ )F 1 strains and (C57BL͞6J ϫ 129͞Sv-K-ras ϩ/Ϫ )F 1 strains, tumor numbers and loads were log transformed, and t tests were applied by using the genotype-genotype differences of the log-transformed values. To facilitate log transformation, multiplicity values of zero were assigned a value of 0.5 and load values of zero were assigned a value of 0.001. These reassignments would produce conservative P values.
Results

Congenic Strains.
We constructed congenic and subcongenic strains carrying various portions of the Pas1 locus on distal chromosome 6 to fine map the candidate region. In the Celera mouse genome map (CDS3.9), the Pas1 locus is within the D6MIT54 and D6MIT373 markers and is located at contigs GAx54KRFPKN04 and GAx6K02T2NTSL, respectively, which define a physical distance of Ϸ36 megabases (Mb). Pas1 congenic strains were constructed by placing this Ϸ36-Mb chromosome 6 region from the A͞J (donor) mice onto the genetic background of the resistant C57BL͞6J (recipient) mice by using a total of nine generations of backcrosses. Nine generations of backcross mating resulted in strains heterozygous for the locus of interest and an overall genome that is Ϸ99.81% C57BL͞6J (16) . After seven generations of backcrosses, 20 male N 7 congenic mice that carried the A͞J donor region (defined by markers D6MIT54 and D6MIT373) were further backcrossed to C57BL͞6J females. Mice with crossovers at various segments throughout the Pas1 region were selected to develop the N 8 generation. A total of 132 male congenic and subcongenic strains (N 8 ) contained various Pas1 subregions. All mice were genotyped with eight microsatellite markers (D6MIT54, D6MIT52, D6MIT59, D6MIT57, D6MCO10, D6MCO11, D6MIT15, and D6MIT373) to define the chromosomal segments from the A͞J mice onto the C57BL͞6J background for each subcongenic strain.
Lung Tumorigenesis of Congenic Mice. Lung tumor bioassays were performed by using the N 9 generation of congenic and subcongenic mice with urethane as the carcinogen. Lung tumor multiplicity and total tumor volume in congenic mice showed a significant difference between the Pas1 congenic strain and its control strain (Fig.  1A ). An average of 6.0 tumors per mouse with a total tumor volume of 1.91 mm 3 was observed in the congenic strain (AB), whereas an average of 0.7 tumor per mouse with a total tumor volume of 0.18 mm 3 was found in the control mice (BB; Fig. 1 A; P Ͻ 0.0001). Replacement of a C57BL͞6J Pas1 allele with an A͞J Pas1 allele increased lung tumor susceptibility by Ϸ8.6-fold in tumor number and Ϸ10-fold in total tumor volume. As a result, the Pas1 QTL was narrowed to an Ϸ0.5-Mb physical region defined by markers D6OSU6 (145.03 Mb) and D6OSU12 (145.53 Mb). (Table 1) . Among these genes, six [Lrmp (17) , Bcat1 (18), Las1 (145.25 Mb), AK015530, Kras2, and AK016641] were confirmed to be expressed in lung tissues by RT-PCR and Northern blot analyses (data not shown). Consistent with our previous study (19) , Northern blot analysis showed that Kras2 4B expression level in A͞J mouse lung was 36% higher than it was in the C57BL͞6J strain, whereas the AK015530 expression level in A͞J mouse lung was 58% lower than it was in C57BL͞6J mouse lung (Fig. 1B) . AK016641 contained an elevated frequency of an alternativesplicing transcript in A͞J (Fig. 1B) . No differential expression was found for Bcat1, Lrmp, and Las1 between lung tissues of A͞J and C57BL͞6J strains (Figs. 1B and 3C ). Next, sequence analyses were performed to detect functional polymorphisms between susceptible and resistant strains. For Lrmp, Bcat1, Kras2, AK016641, and AK015530, the entire ORFs were sequenced. For Las1, additional 5Ј and 3Ј rapid amplification cDNA ends methods were used to obtain the entire ORF. The mouse Las1 sequence and its comparison with those of rat and human are shown in Fig. 2 . As shown in Fig. 1C , four transcripts (AK016641, AK015530, Lrmp, and Las1) showed functional polymorphisms between the A͞J and C67BL͞6J strains. AK016641 had two functional polymorphisms at codon 218 (Arg to His), codon 258 (Gly to Glu), and an alternative splicing transcript without exon 5 that was found only in the A͞J strain. AK015530 had a polymorphism at codon 28, resulting in a change of Gly to Asp. Lrmp had five functional polymorphisms: codon 31 (Asp to Gly), codon 56 (Gly to Asp), codon 58 (Phe to Leu), codon 438 (Arg to Gly), and codon 537 (Pro to Leu). Las1 showed one functional polymorphism at codon 60 (Asn to Ser). Therefore, five genes (AK016641, AK015530, Lrmp, Las1, and Kras2) contained either functional polymorphisms or differential expression between A͞J and C57BL͞6J and were further characterized as candidates for Pas1 gene(s).
Effect of Pas1 Candidates on the Growth of Mouse Lung Tumor Cells.
To evaluate further the effects of Pas1 candidates on cell proliferation, we carried out a series of transfection experiments to determine whether these candidates could promote or inhibit growth of the mouse lung tumor cell lines LM1, MC7, and MC14 (see ref. 22 for detailed descriptions of these cells). Among the five genes (AK016641, AK015530, Lrmp, Las1, and Kras2) tested, only Las1 showed differential effect on cell growth between the A͞J and C57BL͞6J alleles (data not shown for genes with negative results). As shown in Fig. 3Aa , transfection of Las-1-A͞J pcDNA3.1 into LM1 cells produced Ϸ90% colonies vs. pcDNA3.1 control vector, whereas transfection of Las-1-C57BL͞6J pcDNA3.1 produced Ϸ30% colonies vs. pcDNA3.1 control vector, indicating that Las-1-C57BL͞6J pcDNA3.1 significantly inhibited anchoragedependent cell growth (P Ͻ 0.0001; Fig. 3Aa ). Similar inhibitory effects were also observed in MC7 (data not shown) and MC14 (Fig. 3Ab) cells. Clearly, Las1 derived from the C57BL͞6J allele can suppress tumor cell growth in vitro. We also tested the ability of the C57BL͞6J-derived Las1 to inhibit tumor development of LM1 cells in nude mice. As shown in Fig. 3B , after 5 weeks of inoculation, large tumors developed in all four mice injected with Las-1-A͞J pcDNA3.1-transfected cells, but only small tumors developed in the four mice injected with transformed LM1 cells carrying Las-1-C57BL͞6J pcDNA3.1 (P Ͻ 0.05; Fig. 3B b-d) . Expression of Las1 was also confirmed in the resected tumors by RT-PCR (Fig. 3Ba) . These results indicate that the C57BL͞6J-derived Las1 can inhibit the tumorigenic potential of the LM1 cells in vivo.
Strain-Distribution Pattern and Cellular Localization of Las1. Las1 has a 2,193-bp ORF and consists of 730 amino acids; its estimated molecular mass is 84.8 kDa, and it is homologous to axonemal p83.9 (C. intestinalis, Fig. 2 ). Northern blotting showed that Las1 mRNA had a size of Ϸ4 kb and the same expression level between A͞J and C57BL͞6J (Fig. 3Ca) . RT-PCR data also revealed no differential expression in a total of 12 different strains examined, comprising 6 resistant (C57BL͞6J, DBA͞2J, SJL͞J, C3H͞HeJ, AKR͞J, and Mus spretus), 4 intermediate (BALB͞c, 129͞J, CBA͞J, and SM͞J), and 2 susceptible (A͞J and SWR͞J) strains (data not shown). In multiple-organ expression panels, Las1 was expressed at higher levels in lung, kidney, and testis in both A͞J and C57BL͞6J strains (Fig. 3Cb) . Moreover, in 16 mouse cell lines (15), LM2, Spon5, CL-13H, and CL20 showed relatively high levels of Las1 expression, whereas some lines, such as LM1, CMT64, and PCC4, showed extremely low expression (Fig. 3Cc ). There appears to be a close correlation between functional polymorphism of Las1 and lung tumor susceptibility in various mouse strains. We sequenced the entire ORF of the Las1 gene in 12 mouse strains, comprising 6 resistant, 4 intermediate, and 2 susceptible strains. The 12 strains of mice fall into two genotypes according to their sequence alteration in the 60th codon of the Las1 gene. The susceptible͞intermediate groups, including six strains (A͞J, SWR͞J, BALB͞c, 129͞J, CBA͞J, and SM͞J), have an AAT at codon 60 encoding an asparagine, whereas the six resistant strains (C57BL͞6J, DBA͞2J, SJL͞J, C3H͞HeJ, AKR͞J, and M. spretus) have an AGT at codon 60 encoding a serine (data not shown). To assess the possible function of the Las1 gene, the cellular localization of the Las1 product in NIH 3T3, COS7, and LM1 cells was investigated by transient transfection of N-terminal myc-tagged Las1 vectors derived from A͞J and C57BL͞6J alleles into NIH 3T3 cells. Fig. 3D shows the cytoplasmic distribution of the Las1 gene product in NIH 3T3 cells. Similar results were obtained when we transfected those plasmids into COS7 and LM1 cells (data not shown). Looking into Las1 homology between mouse and other species, Las1 products revealed a high degree of conservation from C. intestinalis to human (Fig. 2) . Las1 protein is 67% identical and 81% similar to the derived human LAS1 protein (similar to human hypothetical protein FLJ10921, 30.41 Mb). A search of the National Center for Biotechnology Information (Sept. 26, 2003) protein database using a mouse protein sequence revealed a homologous rat protein, encoded by National Center for Biotechnology Information-predicted gene LOC297720 (84% identities and 92% sim- Fig. 2 . Cluster alignment of mouse, rat, human, and Ciona intestinalis Las1 protein sequences. Identical residues and residues identical in at least two species are shown with black backgrounds. In mouse protein, codon 60 (x) encodes an asparagine (AAT) in A͞J mice and a serine (AGT) in C57BL͞6J mice. The human protein sequence (67% identities and 81% similarities) is based on the predicted human Las1 cDNA sequence. A search of the National Center for Biotechnology Information protein database using the mouse protein sequence revealed a rat homologous protein, encoded by the National Center for Biotechnology Information-predicted gene LOC297720 (84% identities and 92% similarities). The mouse Las1 protein is homologous also to the C. intestinalis protein axonemal p83.9 (GenBank accession no. BAB88834; 33% identities and 52% similarities).
ilarities). The mouse Las1 protein is homologous also to a C. intestinalis protein axonemal p83.9 (accession no. BAB88834; 33% identities and 52% similarities; Fig. 2 ). Axonemes are highly organized microtubule-based structures present in diverse types of cells that perform motile, sensory, and developmental functions in organisms from protists to humans. These functions are consistent with observed cellular distribution.
Kras2 Alleles Contribute to Differential Lung Tumor Progression.
Although no functional polymorphisms were detected in the coding sequence of the Kras2 gene between A͞J mice and C57BL͞6J mice, we further characterized its candidacy for Pas1 because of previously observed allele-specific expression and mutation of Kras2 in mouse lung tumors from hybrid mice, such as (A͞J ϫ C67BL͞6J)F 1 mice or (A͞J ϫ C3H͞HeJ)F 1 mice, in which as much as a 20-fold higher expression of Kras2 mRNA from the A͞J allele was observed (20) . A mouse lung tumor bioassay was conducted by using heterozygous Kras2-deficient mice (K-ras ϩ/Ϫ ). The animals were paired to develop breeding colonies for production of (A͞J ϫ K-ras ϩ/Ϫ )F 1 and (C57BL͞6J ϫ K-ras ϩ/Ϫ )F 1 mice. Either wild-type or heterozygous Kras2-knockout and wild-type mice were subjected to lung tumorigenesis assays using two lung carcinogens: urethane and MNU. Treatment of both heterozygous (A͞J ϫ K-ras ϩ/Ϫ )F 1 -and (C57BL͞6J ϫ K-ras ϩ/Ϫ )F 1 -deficient mice with urethane or MNU produced 4-5 times more tumors per mouse than did treatment of wild-type mice, indicating that no allelic difference was found in promoting lung tumor multiplicity as a result of heterozygous Kras2 deficiency (Fig. 4A) . In contrast, the allelic effects on tumor load (or tumor size) showed significant differences; a nearly 50-fold increase in tumor volume was observed in heterozygous (A͞J ϫ K-ras ϩ/Ϫ )F 1 -deficient mice when compared with wild-type controls, whereas only Ϸ8-fold increase in tumor size was observed in heterozygous (C57BL͞6J ϫ K-ras ϩ/Ϫ )F 1 -deficient mice when compared with wild-type controls (Fig. 4B) . These results indicate that the remaining A͞J or C57BL͞6J Kras2 allele in K-ras ϩ/Ϫ mice has a significant differential effect on lung tumor progression ( Fig.  4B ; P Ͻ 0.001). Thus, the Kras2 allele derived from A͞J mouse strains confers a significantly higher susceptibility to lung tumor progression than does the C57BL͞6J Kras2 allele.
The Activation State of Kras2 in Lung Tumors from Kras2-Deficient
Mice. The mechanism for the Kras2 alleles in lung tumor progression appears to be related to the observed differential mRNA expression of the activated Kras2 alleles in lung tumors from the A͞J strain of mice (20) . Interestingly, there was considerably higher active Kras2 protein expressed in lung tumors from mice containing only an A͞J Kras2 allele compared with mice with only a C57BL͞6J Kras2 allele, as determined by an assay that used the Ras-binding domain of c-Raf to specifically recognize GTP-bound Kras2 (26) (Fig. 4C) . In fact, we were unable to detect any active Kras2 protein in lung tumors from (C57BL͞6J ϫ K-ras ϩ/Ϫ )F 1 mice (Fig. 4C) . This result was seen despite the use of half the amount of lysate in lung tumors from (A͞J ϫ K-ras ϩ/Ϫ )F 1 mice. Thus, mice containing only the C57BL͞6J Kras2 allele expressed less activated Kras2 protein in a fashion that associates closely with its resistance to chemically induced lung tumorigenesis.
Discussion
The Pas1 locus has been associated with susceptibility to mouse lung tumor development after carcinogen treatment (8) (9) (10) (11) (12) (13) (14) . We have demonstrated here that a semidominant A͞J allele contributed to Ϸ8.6-fold differences in lung tumor multiplicity and Ϸ10-fold differences in tumor load between the AB and BB mice. High-resolution mapping using mouse congenic strains has permitted us to narrow the Pas1 QTL to Ϸ0.5 Mb as defined by markers D6OSU6 and D6OSU12. Further characterization of candidate genes by expression analyses, functional polymorphism searches, and colony-formation assay led us to focus on Las1 and Kras2 as primary candidates for Pas1.
The polymorphism of Las1 at codon 60 is consistent with lung tumor susceptibility in mice and the putative Pas1 allele described (6) (7) (8) (9) (10) (11) (12) (13) (14) . Sequence analysis of Las1 and its products revealed a high degree of conservation from C. intestinalis to mammals, which suggests that they may play a fundamental role in cellular proliferation and differentiation. Clearly, mice retaining an A͞J Kras2 allele in heterozygous Kras2-deficient mice are more susceptible to lung tumor progression than those retaining C57BL͞6J Kras2 allele, which provides functional evidence that Kras2 is at least one of the Pas1 genes. Because Kras2 is found to affect only the size of lung tumors, it is likely that Las1 plays an important role in lung tumor multiplicity between the susceptible and resistant strains of mice. The exact relationship between Las1 and Kras2 in promoting tumor multiplicity and tumor progression requires further investigation.
This study also provides evidence that the Kras2 gene is one of the Pas1 genes responsible for lung tumor progression. Two lines of data support this concept. One is the finding that mice retaining an A͞J Kras2 allele in heterozygous Kras2-deficient mice are more susceptible to lung tumor progression than those retaining a C57BL͞6J Kras2 allele, providing functional evidence that Kras2 is at least one of the Pas1 genes. The other is the finding that there was higher active Kras2 protein expressed in lung tumors from mice containing only an A͞J Kras2 allele compared with mice with only a C57BL͞6J Kras2 allele. There was virtually no GTP-bound Kras2 protein detected in lung tumors from (C57BL͞6J ϫ K-ras ϩ/Ϫ )F 1 mice. Thus, the genetic basis for the increased lung tumor progression seen in (A͞J ϫ K-ras ϩ/Ϫ )F 1 mice is due to the higher levels of GTP-bound Kras2 protein. We believe that higher active Kras2 protein associated with the A͞J Kras2 allele is due, at least in part, to the previously observed allele-specific expression and mutation of Kras2 in mouse lung tumors from hybrid mice (20) . Interestingly, the differential expression of RNA or protein seems to occur more frequently during tumorigenesis, suggesting that some of the transcription factors may be made available during the tumorigenic process (20) .
Identification of these two primary candidates, Las1 and Kras2, for lung cancer susceptibility is extremely timely and has an immediate application to humans. Three recent reports have demonstrated that the human PAS1 locus, located in the human 12p12 chromosome region and tightly linked to the KRAS2 gene, is involved in susceptibility to human lung adenocarcinoma (21) (22) (23) . A population-based case-control study showed that the KRAS2͞ RsaI polymorphism is associated with risk and prognosis in both Italian and Japanese lung adenocarcinoma patients, indicating that the human PAS1 mutation may be in this locus (21) . More recently, another case-control study demonstrated that the D12S1034 locus, 800-1,350 kb proximal to the KRAS2 locus, is involved in susceptibility to human lung adenocarcinoma (22) . The potential role of Las1 in human lung cancer should be pursued. The significance of the present study is the finding that human Las1 and Kras2 alleles may predispose some individuals to lung cancer. 
